The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Real-world outcomes of tandem transplantation in patients with newly diagnosed multiple myeloma
Harsh Parmar, MD, Hackensack University Medical Center, Hackensack, NJ, presents results from a study on real-world outcomes of tandem transplantation in patients with high-risk newly diagnosed multiple myeloma (NDMM). Time to next therapy (TTNT) following relapse was significantly longer with the tandem transplantation approach (34 months) compared to a single transplant followed by maintenance therapy (12 months). Similarly, there was a significant increase in overall survival (OS) in patients receiving tandem transplantation, with a decreased adjusted hazard ratio of 0.47 compared to single transplant + maintenance. This provides real-world evidence supporting the use of tandem transplantation in eligible patients with NDMM. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
